<DOC>
	<DOC>NCT00329004</DOC>
	<brief_summary>The purpose of this research study is to determine the highest dose of the drug (BMS-690514) that can be safely given to patients with advanced cancer.</brief_summary>
	<brief_title>A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Men and women 18 and older Diagnosis of any solid tumor ECOG performance status score 01 Prior chemotherapy, immunotherapy or radiotherapy with at least 4 weeks since the last treatment Treatment with VEGFR2 or HER1 TKI allowed but not both (for instance Avastin or Tarceva, but not both) Treatment with other TKIs within the past 4 weeks Patients with brain metastasis Patients with centrally located squamous cell carcinoma of the lung Major gastrointestinal surgery which may affect absorption of the drug Any surgery within last 4 weeks History of thromboembolism Severe unmanageable diarrhea Subjects in Part B will have NonSmall Cell Lung Cancer (NSCLC) Part B/Cohort I erlotinibnaive subjects Part B/Cohort II subjects who have experienced disease progression while receiving erlotinib (erlotinibresistant subjects)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>